These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37311499)

  • 1. Enteric coating of tablets containing an amorphous solid dispersion of an enteric polymer and a weakly basic drug: A strategy to enhance in vitro release.
    Nguyen HT; Van Duong T; Taylor LS
    Int J Pharm; 2023 Jul; 642():123139. PubMed ID: 37311499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Gastric pH Variations on the Release of Amorphous Solid Dispersion Formulations Containing a Weakly Basic Drug and Enteric Polymers.
    Nguyen HT; Van Duong T; Taylor LS
    Mol Pharm; 2023 Mar; 20(3):1681-1695. PubMed ID: 36730186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer.
    Nguyen HT; Van Duong T; Jaw-Tsai S; Bruning-Barry R; Pande P; Taneja R; Taylor LS
    Mol Pharm; 2023 Jun; 20(6):3170-3186. PubMed ID: 37220082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug-Polymer Interactions.
    Hiew TN; Zemlyanov DY; Taylor LS
    Mol Pharm; 2022 Feb; 19(2):392-413. PubMed ID: 34494842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion fabrication for more robust release profiles.
    Duong TV; Nguyen HT; Taylor LS
    Eur J Pharm Biopharm; 2022 May; 174():131-143. PubMed ID: 35413402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Phase Transformations for Amorphous Solid Dispersions of a Weakly Basic Drug upon Dissolution in Biorelevant Media.
    Elkhabaz A; Sarkar S; Simpson GJ; Taylor LS
    Pharm Res; 2019 Oct; 36(12):174. PubMed ID: 31667638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enteric Polymer-Based Amorphous Solid Dispersions Enhance Oral Absorption of the Weakly Basic Drug Nintedanib via Stabilization of Supersaturation.
    Qin Y; Xiao C; Li X; Huang J; Si L; Sun M
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved dissolution of an enteric polymer and its amorphous solid dispersions by polymer salt formation.
    Qi Q; Taylor LS
    Int J Pharm; 2022 Jun; 622():121886. PubMed ID: 35661745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium.
    Luo D; Kim JH; Park C; Oh E; Park JB; Cui JH; Cao QR; Lee BJ
    Int J Pharm; 2017 May; 523(1):343-356. PubMed ID: 28330645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Aluminum Oxide Nanocoating on Drug Release from Amorphous Solid Dispersion Particles.
    Moseson DE; Benson EG; Cao Z; Bhalla S; Wang F; Wang M; Zheng K; Narwankar PK; Simpson GJ; Taylor LS
    Mol Pharm; 2023 Jan; 20(1):593-605. PubMed ID: 36346665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-Dependent supersaturation from amorphous solid dispersions of weakly basic drugs.
    Wang B; Nethercott MJ; Narula A; Hanrahan M; Kuang S; Wenslow RM; Li N
    Pharm Res; 2022 Nov; 39(11):2919-2936. PubMed ID: 34890018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution Behavior of Weakly Basic Pharmaceuticals from Amorphous Dispersions Stabilized by a Poly(dimethylaminoethyl Methacrylate) Copolymer.
    Frank DS; Prasad P; Iuzzolino L; Schenck L
    Mol Pharm; 2022 Sep; 19(9):3304-3313. PubMed ID: 35985017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed dose combinations for cardiovascular treatment via coaxial electrospraying: Coated amorphous solid dispersion particles.
    Smeets A; Re IL; Clasen C; Van den Mooter G
    Int J Pharm; 2020 Mar; 577():118949. PubMed ID: 31837403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution.
    Jara MO; Warnken ZN; Sahakijpijarn S; Thakkar R; Kulkarni VR; Christensen DJ; Koleng JJ; Williams RO
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating the effect of crystallization on drug release from amorphous solid dispersions in soluble and insoluble carriers.
    Ojo AT; Ma C; Lee PI
    Int J Pharm; 2020 Dec; 591():120005. PubMed ID: 33132149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leaching of Lopinavir Amorphous Solid Dispersions in Acidic Media.
    Li N; Ormes JD; Taylor LS
    Pharm Res; 2016 Jul; 33(7):1723-35. PubMed ID: 27026009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions.
    Tanno F; Nishiyama Y; Kokubo H; Obara S
    Drug Dev Ind Pharm; 2004 Jan; 30(1):9-17. PubMed ID: 15000425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
    Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
    Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Effects of Supersaturation Rates and Doses on the Kinetic-Solubility Profiles of Amorphous Solid Dispersions Based on Water-Insoluble Poly(2-hydroxyethyl methacrylate) Hydrogels.
    Schver GCRM; Lee PI
    Mol Pharm; 2018 May; 15(5):2017-2026. PubMed ID: 29601723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.